Characterization of multiple driver alterations in acquired resistance to osimertinib in EGFR-mutated lung cancer: implementation of single cell approaches

被引：0
|
作者：
Chen, Jeanne [1 ]
Braye, Floriane [1 ]
Facchinetti, Francesco [1 ]
Lacroix, Ludovic [1 ]
Scoazec, Jean-Yves [1 ]
Tselikas, Lambros [1 ]
Planchard, David [1 ]
Mezquita, Laura [1 ]
Gazzah, Anas [1 ]
Naltet, Charles [1 ]
Lavaud, Pernelle [1 ]
Maillard, Aline [1 ]
Michiels, Stefan [1 ]
Massard, Christophe [1 ]
Olaussen, KenA [1 ]
Andr, Fabrice [1 ]
Vassal, Gilles [1 ]
Soria, Jean-Charles [1 ]
Besse, Benjamin [1 ]
Friboulet, Luc [1 ]
机构：
[1] Inst Gustave Roussy, Villejuif, France
来源：
CANCER RESEARCH | 2020年 / 80卷 / 16期
关键词：
D O I：
10.1158/1538-7445.AM2020-1867
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1867
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Osimertinib then chemotherapy in EGFR-mutated lung cancer with osimertinib third-line rechallenge (OCELOT).
    Breadner, Daniel Adam
    Vincent, Mark David
    Liu, Geoffrey
    Rothenstein, Jeffrey
    Menjak, Ines B.
    Cheema, Parneet Kaur
    Juergens, Rosalyn A.
    Mithoowani, Hamid
    Bains, Puneet
    Wang, Ying
    Wheatley-Price, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [22] Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
    Uchibori, Ken
    Inase, Naohiko
    Araki, Mitsugu
    Kamada, Mayumi
    Sato, Shigeo
    Okuno, Yasushi
    Fujita, Naoya
    Katayama, Ryohei
    NATURE COMMUNICATIONS, 2017, 8
  • [23] Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
    Ken Uchibori
    Naohiko Inase
    Mitsugu Araki
    Mayumi Kamada
    Shigeo Sato
    Yasushi Okuno
    Naoya Fujita
    Ryohei Katayama
    Nature Communications, 8
  • [24] Afatinib After Progression on Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer
    Aredo, Jacqueline, V
    Wakelee, Heather A.
    Neal, Joel W.
    Padda, Sukhmani K.
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2022, 30
  • [25] Author Correction: Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer
    Juliann Chmielecki
    Jhanelle E. Gray
    Ying Cheng
    Yuichiro Ohe
    Fumio Imamura
    Byoung Chul Cho
    Meng-Chih Lin
    Margarita Majem
    Riyaz Shah
    Yuri Rukazenkov
    Alexander Todd
    Aleksandra Markovets
    J. Carl Barrett
    Ryan J. Hartmaier
    Suresh S. Ramalingam
    Nature Communications, 14
  • [26] Osimertinib in EGFR-Mutated Lung Cancer: A Review of the Existing and Emerging Clinical Data
    Lee, Chung-Shien
    Milone, Matthew
    Seetharamu, Nagashree
    ONCOTARGETS AND THERAPY, 2021, 14 : 4579 - 4597
  • [27] Overcoming EGFR-TKI resistance in EGFR-mutated lung cancer
    Gardizi, M.
    Scheffler, M.
    Bos, M.
    Geist, T.
    Heukamp, L.
    Nogova, L.
    Toepelt, K.
    Fernandez-Cuesta, L.
    Culmann, H.
    Kaminsky, B.
    Panse, J.
    Becker, C.
    Mattonet, C.
    Serke, M.
    Schmitz, S.
    Schnell, R.
    Galetke, W.
    Hekmat, K.
    Buettner, R.
    Wolf, J.
    ONKOLOGIE, 2013, 36 : 30 - 30
  • [28] Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial
    Chmielecki, Juliann
    Mok, Tony
    Wu, Yi-Long
    Han, Ji-Youn
    Ahn, Myung-Ju
    Ramalingam, Suresh S.
    John, Thomas
    Okamoto, Isamu
    Yang, James Chih-Hsin
    Shepherd, Frances A.
    Bulusu, Krishna C.
    Laus, Gianluca
    Collins, Barbara
    Barrett, J. Carl
    Hartmaier, Ryan J.
    Papadimitrakopoulou, Vassiliki
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [29] Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer (14, 1070, 2023)
    Chmielecki, Juliann
    Gray, Jhanelle E.
    Cheng, Ying
    Ohe, Yuichiro
    Imamura, Fumio
    Cho, Byoung Chul
    Lin, Meng-Chih
    Majem, Margarita
    Shah, Riyaz
    Rukazenkov, Yuri
    Todd, Alexander
    Markovets, Aleksandra
    Barrett, J. Carl
    Hartmaier, Ryan J.
    Ramalingam, Suresh S.
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [30] Brigatinib, a newly discovered AXL inhibitor, suppresses AXL-mediated acquired resistance to osimertinib in EGFR-mutated non-small cell lung cancer
    Han, Rui
    Lu, Cong-hua
    Hu, Chen
    Dou, Yuan-yao
    Kang, Jun
    Lin, Cai-yu
    Wu, Di
    Jiang, Wei-ling
    Yin, Guo-qing
    He, Yong
    ACTA PHARMACOLOGICA SINICA, 2024, 45 (06) : 1264 - 1275
12345